Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $39.6 million.

  • Editas Medicine's Cash from Investing Activities fell 5287.75% to $39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.6 million, marking a year-over-year decrease of 1260.64%. This contributed to the annual value of $162.1 million for FY2024, which is 444591.26% up from last year.
  • Per Editas Medicine's latest filing, its Cash from Investing Activities stood at $39.6 million for Q3 2025, which was down 5287.75% from $42.6 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Cash from Investing Activities ranged from a high of $89.2 million in Q3 2022 and a low of -$102.8 million during Q3 2023
  • For the 5-year period, Editas Medicine's Cash from Investing Activities averaged around $18.8 million, with its median value being $23.3 million (2023).
  • Per our database at Business Quant, Editas Medicine's Cash from Investing Activities surged by 163770.04% in 2022 and then crashed by 21523.42% in 2023.
  • Quarter analysis of 5 years shows Editas Medicine's Cash from Investing Activities stood at -$22.8 million in 2021, then fell by 20.53% to -$27.5 million in 2022, then soared by 328.28% to $62.8 million in 2023, then tumbled by 50.74% to $31.0 million in 2024, then rose by 27.83% to $39.6 million in 2025.
  • Its Cash from Investing Activities stands at $39.6 million for Q3 2025, versus $42.6 million for Q2 2025 and $56.4 million for Q1 2025.